Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.

Javier Melchor Marcos Garcia-Lacarte Sara C Grijalba Adrián Arnaiz-Leché Marién Pascual Carlos Panizo Oscar Blanco Victor Segura Francisco Javier Novo Juan Garcia Valero Patricia Pérez-Galán Jose-Angel Martinez-Climent Sergio Roa

Published in: Journal for immunotherapy of cancer (2023)

These results suggest that the combination of anti-CD20-based immunotherapy and BCL2 inhibition leads to cooperative immunomodulatory effects and improved preclinical responses, which may offer promising therapeutic opportunities for DEL-DLBCL patients.

Keyphrases

diffuse large b cell lymphoma
mouse model
epstein barr virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
cell therapy
patient reported